Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.
Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M, Kahan JP. Poston GJ, et al. Among authors: schmoll hj. J Clin Oncol. 2005 Oct 1;23(28):7125-34. doi: 10.1200/JCO.2005.08.722. J Clin Oncol. 2005. PMID: 16192596
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ. Shah MA, et al. Among authors: schmoll hj. J Clin Oncol. 2016 Mar 10;34(8):843-53. doi: 10.1200/JCO.2015.63.0558. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811529 Free PMC article.
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E. Schmoll HJ, et al. J Clin Oncol. 2012 Oct 10;30(29):3588-95. doi: 10.1200/JCO.2012.42.5355. Epub 2012 Sep 10. J Clin Oncol. 2012. PMID: 22965961 Clinical Trial.
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG. Schmoll HJ, et al. J Clin Oncol. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324362 Clinical Trial.
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.
Papamichael D, Renfro LA, Matthaiou C, Yothers G, Saltz L, Guthrie KA, Van Cutsem E, Schmoll HJ, Labianca R, André T, O'Connell M, Alberts SR, Haller DG, Kountourakis P, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group. Papamichael D, et al. Among authors: schmoll hj. J Geriatr Oncol. 2016 Nov;7(6):422-429. doi: 10.1016/j.jgo.2016.07.002. Epub 2016 Jul 25. J Geriatr Oncol. 2016. PMID: 27468630 Free PMC article.
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard JY, Gustavsson BG, Milano G, O'Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzén F, Twelves C. Haller DG, et al. Among authors: schmoll hj. J Clin Oncol. 2008 May 1;26(13):2118-23. doi: 10.1200/JCO.2007.15.2090. J Clin Oncol. 2008. PMID: 18445840
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.
Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, Daisne JF, Janssens J, Brenner B, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig CV, Zalcberg J, Tebbutt N, Mauer ME, Marreaud S, Lutz MP, Haustermans K. Schmoll HJ, et al. J Clin Oncol. 2021 Jan 1;39(1):17-29. doi: 10.1200/JCO.20.01740. Epub 2020 Oct 1. J Clin Oncol. 2021. PMID: 33001764 Clinical Trial.
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Schmoll HJ, et al. J Clin Oncol. 2007 Jan 1;25(1):102-9. doi: 10.1200/JCO.2006.08.1075. J Clin Oncol. 2007. PMID: 17194911 Clinical Trial.
Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer.
Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Pucciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F. Lutz MP, et al. Among authors: schmoll hj. Eur J Cancer. 2016 Aug;63:11-24. doi: 10.1016/j.ejca.2016.04.010. Epub 2016 May 30. Eur J Cancer. 2016. PMID: 27254838 Free article.
439 results